Pharvaris, a late-stage biopharmaceutical company based in Zug, Switzerland, has announced a virtual R&D call titled "Deucrictibant: Beyond HAE Type 1/2" scheduled for June 4, 2025. This event will ...
Pharvaris, a biopharmaceutical company focusing on innovative oral treatments for bradykinin-mediated diseases like hereditary angioedema (HAE), recently shared data from the European Academy of ...
Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data ...
Please provide your email address to receive an email when new articles are posted on . One adverse event was recorded in the treatment group. An attack rate reduction of 93% was seen in the treatment ...
ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ...
woman with swollen eye A single dose of PHA-022121, an oral beta-2 antagonist, was associated with effective bradykinin-inhibiting concentrations within 15 minutes of administration in patients with ...
Cold activation of plasma from people living with HAE resulted in increased levels of bradykinin compared to cold-activated plasma of healthy volunteers, resulting in a qualified kinin assay that can ...
Hereditary angioedema (HAE) is a rare, autosomal dominant disorder defined by episodic, potentially life‐threatening swellings that can affect the skin, gastrointestinal tract, and upper airways.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback